Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)
UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen UKONIQ is approved for adult patients with relapsed or refractory follicular lymphoma after at least three prior lines of systemic therapy UKONIQ is the first
Feb 05, 2021
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference
Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET NEW YORK , Jan. 15, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during
Jan 15, 2021
TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET NEW YORK , Jan. 08, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the 39 th Annual J.P.
Jan 08, 2021
Displaying 41 - 43 of 43